For the year ending 2025-12-31, XERS made $291,845K in revenue. $554K in net income. Net profit margin of 0.19%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Product revenue, net | 291,845 | 203,070 | ||
| Cost of goods sold | 42,569 | 36,832 | ||
| Research and development | 31,165 | 25,560 | ||
| Selling, general and administrative | 182,372 | 163,481 | ||
| Amortization of intangible assets | 10,843 | 10,843 | ||
| Total costs and expenses | 266,949 | 236,716 | ||
| Income (loss) from operations | 24,896 | -33,646 | ||
| Interest and other income | 4,742 | 5,321 | ||
| Loss on debt extinguishment, net | 0 | - | ||
| Debt refinancing costs | 0 | 2,690 | ||
| Interest expense | 29,084 | 30,485 | ||
| Change in fair value of warrants | 0 | -8 | ||
| Change in fair value of contingent value rights | 0 | -4,388 | ||
| Total other expense | -24,342 | -23,458 | ||
| Net income (loss) before income taxes | 554 | -57,104 | ||
| U.s. federal statutory tax rate | -116 | - | ||
| State and local income taxes, net of federal income tax effect | 0 | - | ||
| Statutory tax rate difference between ireland and united states-IE | 3,832 | - | ||
| Changes in valuation allowance-IE | 6,061 | - | ||
| Other | 49 | - | ||
| Statutory tax rate difference between ireland and united states-Foreign Tax Jurisdiction Other | 290 | - | ||
| Subpart f income | -12,606 | - | ||
| Research and development tax credits | -1,224 | - | ||
| Changes in valuation allowance-US | 3,712 | - | ||
| Compensation subject to the section 162 limitation | -1,276 | - | ||
| Stock compensation | -795 | - | ||
| Non-deductible expenses | -277 | - | ||
| Other adjustments | -98 | - | ||
| Income tax benefit | 0 | -2,268 | ||
| Net income (loss) | 554 | -54,836 | ||
| Unrealized gains (losses) on investments | 0 | - | ||
| Comprehensive income (loss) | 554 | -54,836 | ||
| Basic EPS | 0 | -0.37 | ||
| Diluted EPS | 0 | -0.37 | ||
| Basic Average Shares | 160,425,198 | 146,772,758 | ||
| Diluted Average Shares | 172,742,720 | 146,772,758 | ||
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)